Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Analyst Says
1. Berenberg upgraded NOVO.B to 'Buy' after a favorable analysis. 2. New CEO potentials create optimism despite recent performance downturns. 3. Upcoming Wegovy pill launch could enhance market competitiveness. 4. Analysts see potential in NOVO.B's pipeline against Eli Lilly. 5. Market share gains for Lilly's Zepbound are reportedly stalling.